Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, demonstrated its human papillomavirus (HPV) diagnostic products and underscored the critical importance of HPV screening test at the Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN) conference, held in Seoul, South Korea from July 11-13.

At the AOGIN, Seegene presented its advanced technologies for identifying viruses linked to cervical cancer. The company organized an exhibition booth and hosted a symposium session under the theme of ‘Navigating clinical guidelines and implementations for HPV cervical cancer screening.’

The company showcased its unique quantitative PCR technology-based HPV diagnostic products, ‘Allplex HPV HR Detection’ and ‘Allplex HPV28 Detection’.

The Allplex HPV HR Detection is designed to test for 14 high-risk HPVs, including types 16 and 18, in a single tube. The Allplex HPV28 Detection is designed to test for 28 HPVs, in two tubes, including 19 high-risk types and 9 low-risk types, in two tubes. The products are ideal for cervical cancer prevention and follow-up management.

The company also introduced Seegene’s STARlet-AIOS, a fully automated molecular diagnostic testing system that streamlines the entire PCR process from nucleic acid extraction to result analysis, along with SG STATS, the company’s premium platform of advanced statistical analysis.

Daniel Shin, Executive Vice-President and Chief Global Sales and Marketing Officer at Seegene said, “We are currently operating a campaign in the global market to raise awareness about the benefits of syndromic PCR testing, including simultaneous testing for HPV and sexually transmitted infections (STIs). We believe the campaign will pave the way for the widespread adoption of syndromic PCR testing, helping to realise  “a world free from all diseases.”